

*Unless otherwise defined herein, capitalized terms in this announcement shall have the same meanings as those defined in the prospectus dated September 5, 2017 (the “**Prospectus**”) issued by Sisram Medical Ltd (the “**Company**”).*

*Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and Hong Kong Securities Clearing Company Limited (“**HKSCC**”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

This announcement is for information purposes only and does not constitute an offer or an invitation to induce an offer by any person to acquire, purchase or subscribe for securities. Potential investors should read the Prospectus for detailed information about the Company and the Global Offering described below before deciding whether or not to invest in the Shares thereby offered.

*This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). This announcement does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States. The Shares have not been, and will not be, registered under the United States Securities Act of 1933, as amended from time to time (the “**U.S. Securities Act**”). The securities may not be offered or sold in the United States except pursuant to registration or an exemption from the registration requirements of the U.S. Securities Act. There will be no public offer of securities by the Company in the United States, the State of Israel or any jurisdiction other than Hong Kong.*

*In connection with the Global Offering, China International Capital Corporation Hong Kong Securities Limited, as stabilizing manager (the “**Stabilizing Manager**”), its affiliates or any person acting for it, on behalf of the Underwriters, may effect transactions with a view to stabilizing or supporting the market price of the Shares at a level higher than that which might otherwise prevail for a limited period after the Listing Date. However, there is no obligation on the Stabilizing Manager, its affiliates or any person acting for it, to conduct any such stabilizing action, which, if commenced, will be done at the sole and absolute discretion of the Stabilizing Manager, its affiliates or any person acting for it, and may be discontinued at any time. Any such stabilizing activity is required to be brought to an end on the 30th day after the last day for the lodging of applications under the Hong Kong Public Offering. Such stabilization action, if commenced, may be effected in all jurisdictions where it is permissible to do so, in each case in compliance with all applicable laws, rules and regulatory requirements, including the Securities and Futures (Price Stabilizing) Rules, as amended, made under the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).*

Potential investors should be aware that stabilizing action cannot be taken to support the price of the Shares for longer than the stabilization period which begins on the Listing Date and is expected to expire on Sunday, October 8, 2017, being the 30th day after the last day for the lodging of applications under the Hong Kong Public Offering. After this date, no further stabilizing action may be taken, demand for the Shares, and therefore the price of the Shares, could fall.

Sisram Medical Ltd

(Incorporated in Israel with limited liability)

Global Offering

- Number of Offer Shares under the Global Offering** : 110,000,000 Shares (comprising 88,000,000 New Shares and 22,000,000 Sale Shares, and subject to the Over-allotment Option)
- Number of Hong Kong Offer Shares** : 11,000,000 New Shares (subject to reallocation)
- Number of International Offer Shares** : 99,000,000 Shares (comprising 77,000,000 New Shares and 22,000,000 Sale Shares, and subject to reallocation and the Over-allotment Option)
- Maximum Offer Price** : HK\$12.35 per Offer Share, plus brokerage of 1%, SFC transaction levy of 0.0027% and Stock Exchange trading fee of 0.005% (payable in full on application in Hong Kong dollars and subject to refund)
- Nominal value** : NIS0.01 per Share
- Stock code** : 1696

Joint Sponsors, Joint Global Coordinators, Joint Bookrunners and Joint Lead Managers
(in alphabetical order)



Jefferies

Joint Global Coordinator, Joint Bookrunner and Joint Lead Manager

FOSUN HANI
复星恒利

Joint Bookrunners and Joint Lead Managers



The Company is initially offering 110,000,000 Shares (subject to the Over-allotment Option) under the Global Offering, which consists of 11,000,000 Hong Kong Offer Shares (subject to reallocation) and 99,000,000 International Offer Shares (subject to reallocation and the Over-allotment Option), representing 10% and 90% of the total number of Shares initially available under the Global Offering, respectively. Of the 99,000,000 Offer Shares initially being offered under the International Offering, 5,500,000 Offer Shares, representing 5% of the shares offered under the Global Offering, will be offered to Qualifying Fosun International Shareholders as an Assured Entitlement by way of the Preferential Offering. The allocation of the Offer Shares between the International Offering and the Hong Kong Public Offering, in each case, will be subject to reallocation on the basis as described in the section headed “Structure of the Global Offering” in the Prospectus. The Reserved Shares are not subject to such reallocation.

An application has been made by the Company to the Listing Committee of the Stock Exchange for the approval for the listing of, and permission to deal in, the Shares in issue and to be issued pursuant to the Capitalization Issue and the Global Offering (including any additional Shares which may be issued pursuant to the exercise of the Over-allotment Option).

Subject to the granting of the approval for the listing of, and permission to deal in, the Shares on the Stock Exchange and compliance with the stock admission requirements of HKSCC, the Shares will be accepted as eligible securities by HKSCC for deposit, clearance and settlement in CCASS with effect from the date of commencement of dealings in the Shares on the Stock Exchange, or such other date as may be determined by HKSCC. Settlement of transactions between participants of the Stock Exchange is required to take place in CCASS on the second Business Day after any trading day. All activities under CCASS are subject to the General Rules of CCASS and the CCASS Operational Procedures in effect from time to time. All necessary arrangements have been made to enable the Shares to be admitted into CCASS.

In connection with the Global Offering, the Company is expected to grant the Over-allotment Option to the International Underwriters, exercisable by the Joint Global Coordinators (on behalf of the International Underwriters) up to the 30th day following the last day for the lodging of applications under the Hong Kong Public Offering. Pursuant to which the Company may be required to issue and allot up to an aggregate of 16,500,000 Shares, representing 15% of the number of Offer Shares initially available under the Global Offering at the Offer Price to cover over-allocations in the International Offering, if any.

Assuming that the Hong Kong Public Offering becomes unconditional at or before 8:00 a.m. in Hong Kong on Tuesday, September 19, 2017, it is expected that dealings in the Shares on the Stock Exchange will commence at 9:00 a.m. on Tuesday, September 19, 2017. In the event that the Over-allotment Option is exercised, an announcement will be made by the Company on the websites of the Stock Exchange at www.hkexnews.hk and the Company at www.sisram-medical.com.

The Offer Price will not be more than HK\$12.35 per Offer Shares and is expected to be not less than HK\$8.88 per Offer Share unless otherwise announced. Applicants for the Hong Kong Offer Shares are required to pay, on application, the Maximum Offer Price of HK\$12.35 per Offer Share plus brokerage of 1.0%, SFC transaction levy of 0.0027% and Stock Exchange trading fee of 0.005%, subject to refund if the Offer Price as finally determined is less than HK\$12.35 per Offer Share.

Applications for the Hong Kong Offer Shares and Reserved Shares will only be considered on the basis of the terms and conditions set out in the Prospectus, the relevant Application Forms and the designated website (www.eipo.com.hk) for the White Form eIPO and the Blue Form eIPO.

IMPORTANT

The Company will be relying on Section 9A of the Companies (Exemption of Companies and Prospectuses from Compliance with Provisions) Notice (Chapter 32L of the Laws of Hong Kong) and will be issuing (a) the **WHITE** and **YELLOW** Application Forms without them being accompanied by a printed Prospectus and (b) the **BLUE** Application Forms to the relevant Qualifying Fosun International Shareholders without them being accompanied by a printed Prospectus, unless the relevant Qualifying Fosun International shareholders have elected to receive corporate communications in printed form under Fosun International's corporate communications policy or have not been asked to elect the means of receiving Fosun International's corporate communications, in which case the printed Prospectus will be dispatched to them separately. The contents of the printed Prospectus are identical to the electronic version of the Prospectus which can be accessed and downloaded from the websites of the Company at www.sisram-medical.com and the Stock Exchange at www.hkexnews.hk under the "*HKExnews > Listed Company Information > Latest Listed Company Information*" section, respectively.

Applicants who would like to be allotted Hong Kong Offer Shares registered in their own names should (i) complete and sign the **WHITE** Application Forms; or (ii) submit applications online through the designated website of the **White Form eIPO** Service Provider at www.eipo.com.hk under the **White Form eIPO** service. Applicants who would like to have the allotted Hong Kong Offer Shares registered in the name of HKSCC Nominees and deposited directly into CCASS for credit to

their designated CCASS Participants' stock accounts or their CCASS Investor Participant stock accounts or the stock accounts of their designated CCASS participants maintained in CCASS should either (i) complete and sign the **YELLOW** Application Forms; or (ii) give **electronic application instructions** to HKSCC via CCASS. Qualifying Fosun International Shareholders who wish to apply for the Reserved Shares under the Preferential Offering should either (i) complete and sign the BLUE Application Forms or (ii) submit applications online through the designated website of the **Blue Form eIPO** Service provider at www.eipo.com.hk under the **Blue Form eIPO** service.

Members of the public and Qualifying Fosun International Shareholders may obtain a copy of the printed prospectus, free of charge, upon request during normal business hours from 9:00 a.m. on Tuesday, September 5, 2017 until 12:00 noon on Friday, September 8, 2017 at the following locations:

1. any of the following branches of the receiving bank for the Hong Kong Public Offering:

	Branch Name	Address
Hong Kong Island	88 Des Voeux Road Branch	88 Des Voeux Road Central, Central
Kowloon	Mongkok Branch	Shop B, G/F, 1/F & 2/F, 617-623 Nathan Road, Mongkok
New Territories	Tsuen Wan Branch	Shop C, G/F & 1/F, Jade Plaza, 298 Sha Tsui Road, Tsuen Wan

2. any of the following offices of the Hong Kong Underwriters:
 - (a) China International Capital Corporation Hong Kong Securities Limited, at 29th Floor, One International Finance Centre, 1 Harbour View Street, Central, Hong Kong; and
 - (b) Jefferies Hong Kong Limited, at Suite 2201, 22/F, Cheung Kong Center, 2 Queen's Road Central, Central, Hong Kong; and
 - (c) Fosun Hani Securities Limited, at Suite 2101-2105, 21/F, Champion Tower, 3 Garden Road, Central, Hong Kong; and
 - (d) Haitong International Securities Company Limited, 22/F, Li Po Chun Chambers, 189 Des Voeux Road Central, Hong Kong; and
 - (e) Huatai Financial Holdings (Hong Kong) Limited, Room 5801-05 & 08-12, 58/F, The Center, 99 Queen's Road Central, Hong Kong.

Copies of the Prospectus, together with the **YELLOW** Application Forms, may be obtained during normal business hours from 9:00 a.m. on Tuesday, September 5, 2017 until 12:00 noon on Friday, September 8, 2017 from the Depository Counter of HKSCC at 1/F, One & Two Exchange Square, 8 Connaught Place, Central, Hong Kong.

Details of where printed Prospectuses will be displayed prominently at every designated branch of receiving bank where WHITE Application Forms are distributed:

Standard Chartered Bank (Hong Kong) Limited

Hong Kong Island	88 Des Voeux Road Branch	88 Des Voeux Road Central, Central
	Hennessy Road Branch	399 Hennessy Road, Wanchai
	North Point Centre Branch	Shop G, G/F, North Point Centre, 284 King's Road, North Point
Kowloon	Mongkok Branch	Shop B, G/F, 1/F & 2/F, 617-623 Nathan Road, Mongkok
	Telford Gardens Branch	Shop P9-12, Telford Centre, Telford Gardens, Tai Yip Street, Kwun Tong
New Territories	Tsuen Wan Branch	Shop C, G/F & 1/F, Jade Plaza, 298 Sha Tsui Road, Tsuen Wan
	Tseung Kwan O Branch	Shop G37-40, G/F, Hau Tak Shopping Centre East Wing, Hau Tak Estate, Tseung Kwan O

During normal business hours from 9:00 a.m. on Tuesday, September 5, 2017 until 12:00 noon on Friday, September 8, 2017, at least three copies of the printed Prospectus will be available for inspection at every location where the **WHITE** and **YELLOW** Application Forms are distributed as set out in “How to Apply for Hong Kong Offer Shares and Reserved Shares” in the Prospectus.

Both **WHITE** or **YELLOW** Application Forms completed in all respects in accordance with the instructions printed thereon, to which cheques or banker's cashier orders payable to "**HORSFORD NOMINEES LIMITED - SISRAM MEDICAL PUBLIC OFFER**" should be securely stapled, should be deposited in the special collection boxes provided at any of the designated branches of the receiving bank listed above on the following dates and during the following times:

Tuesday, September 5, 2017 — 9:00 a.m. to 5:00 p.m.
Wednesday, September 6, 2017 — 9:00 a.m. to 5:00 p.m.
Thursday, September 7, 2017 — 9:00 a.m. to 5:00 p.m.
Friday, September 8, 2017 — 9:00 a.m. to 12:00 noon

A **BLUE** Application Form, and prospectus (if the related Qualifying Fosun International shareholders have elected to receive corporate communications in printed form) has been dispatched to each Qualifying Fosun International Shareholder on or before Tuesday, September 5, 2017. Electronic copies of the Prospectus can be viewed from the respective websites of the Company at www.sisram-medical.com and the Stock Exchange at www.hkexnews.hk under the section headed "HKEXnews > Listed Company Information > Latest Information".

Qualifying Fosun International Shareholders who require a replacement **BLUE** Application Form should contact Computershare Hong Kong Investor Services Limited at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong or on its hotline 2862 8555. Printed copies of the Prospectus can be collected from the branches of the designated receiving bank or the offices of the Joint Global Coordinators as stated above.

Applicants may submit applications through the **White Form eIPO** service or **Blue Form eIPO** service through the designated website at www.eipo.com.hk (24 hours daily, except on the last day for applications) from 9:00 a.m. on Tuesday, September 5, 2017 until 11:30 a.m. on Friday, September 8, 2017 or such later time as described in the section headed "How to Apply for Hong Kong Offer Shares and Reserved Shares — D. Effect of Bad Weather on the Opening and Closing of the Application Lists" in the Prospectus.

CCASS Participants can input **electronic application instructions** (24 hours daily, except on the last day for applications) from 9:00 a.m. on Tuesday, September 5, 2017 until 12:00 noon on Friday, September 8, 2017 (or such later time as described in "How to Apply for Hong Kong Offer Shares and Reserved Shares — D. Effect of Bad Weather on the Opening and Closing of the Application Lists" in the Prospectus).

Please refer to the sections headed “Structure of the Global Offering” and “How to Apply for Hong Kong Offer Shares and Reserved Shares” in the Prospectus for details of the conditions and procedures of the Hong Kong Public Offering.

The Company expects to announce the final Offer Price, the level of indication of interest in the International Offering, the level of applications in the Hong Kong Public Offering and the Preferential Offering and the basis of allocation of the Hong Kong Offer Shares and the Reserved Shares (i) in South China Morning Post (in English); (ii) in Hong Kong Economic Times (in Chinese); (iii) on our website www.sisram-medical.com and (iv) on the website of the Stock Exchange www.hkexnews.hk on Monday, September 18, 2017.

The results of allocations and the Hong Kong identity card/ passport/Hong Kong business registration numbers of successful applicants under the Hong Kong Public Offering and the Preferential Offering will be made available in a manner described in the section entitled “How to Apply for Hong Kong Offer Shares and Reserved Shares — E. Publication of Results” in the Prospectus on Monday, September 18, 2017.

The Company will not issue temporary documents of title or receipt for application fees received. Share certificates will only become valid certificates of title at 8:00 a.m. on Tuesday, September 19, 2017 provided that the Global Offering has become unconditional in all respects and the right of termination described in the section headed “Underwriting” has not been exercised.

To comply with the reporting obligations under Israeli Companies Law, the Company is required to file a report with the Israeli Companies Registrar containing certain information on the shareholders whose names appear on the register of members of the Company. The documents required to be provided by such shareholders are set out in “How to Apply for Hong Kong Offer Shares and Reserved Shares” in the Prospectus and the **WHITE** and **BLUE** Application Forms.

Dealings in the Shares on the Stock Exchange are expected to commence at 9:00 a.m. on Tuesday, September 19, 2017. The Shares will be traded in board lots of 400 Shares each under the Company's stock code 1696.

By order of the Board of Directors
Sisram Medical Ltd
Yi LIU
Chairman

Hong Kong, September 5, 2017

As at the date of this announcement, the executive Directors are Mr. Yi LIU and Mr. Lior Moshe DAYAN; the non-executive Directors are Mr. Yifang WU, Mr. Chun LI, Mr. Yao WANG and Ms. Yu HU; the independent non-executive Directors are Mr. Heung Sang Addy FONG, Mr. Chi Fung Leo CHAN, Ms. Jenny CHEN and Mr. Kai Yu Kenneth LIU.

Please also refer to the published version of this announcement in the South China Morning Post (in English) and the Hong Kong Economic Times (in Chinese).